Page 1

Hypera pharma Hypera Pharma reports Net Revenue growth of 43.5 % in 2Q21 , with EBITDA from Continuing Operations expansion of 31.8 % São Paulo , July 23 , 2021 – Hypera S.A. ( “ Hypera Pharma ” or “ Company ” ; B3 : HYPE3 ; Bloomberg : HYPE3 BZ ; ISIN : BRHYPEACNORO ; Reuters : HYPE3.SA ; ADR : HYPMY ) announces its financial results for the 2nd quarter of 2021. Financial data disclosed here are taken from the consolidated financial statements of Hypera S.A. , prepared in accordance with the Brazilian Accounting Pronouncement Committee ( CPC ) and International Financial Reporting Standards ( IFRS ) issued by the International Accounting Standards Board ( IASB ) . 2Q21 Highlights • Net revenue of R $ 1,507.4 million in the quarter , or 43.5 % higher than 2Q20 • • • EBITDA from Continuing Operations of R $ 591.9 million , or 31.8 % higher than 2Q20 Net Income from Continuing Operations of R $ 479.4 million , an increase of 20.1 % over 2Q20 Organic Sell - out growth of 23.3 % ¹ in 2Q21 , or 1.1 p.p. above the market² , according to IQVIA • Interest on Equity Approval of R $ 194.8 million in 2Q21 , or 5 % greater than 2Q20 • Acquisition of a portfolio of 12 medicines from Sanofi • Acquisition of Bioage , a leading brand in the Brazilian aesthetics market Table 1 ( R $ million ) 2Q20 % NR 2Q21 % NR A % 1H20 % NR 1H21 % NR A % Gross Revenue , net of Returns and Unconditional Discounts 1,201.3 Net Revenue 1,050.5 114.4 % 1,725.7 100.0 % 1,507.4 114.5 % 43.7 % 2,112.9 113.3 % 3,057.2 114.2 % 44.7 % 100.0 % 43.5 % 1,865.5 100.0 % 2,678.2 100.0 % 43.6 % Gross Profit 690.3 65.7 % 987.7 65.5 % 43.1 % 1,233.3 66.1 % 1,740.5 65.0 % 41.1 % SG & A ( ex - Marketing and R & D ) ( 154.2 ) -14.7 % ( 182.0 ) -12.1 % 18.0 % ( 299.4 ) -16.0 % ( 348.8 ) -13.0 % 16.5 % Marketing ( 187.2 ) -17.8 % ( 298.3 ) -19.8 % 59.4 % ( 369.7 ) -19.8 % ( 513.0 ) -19.2 % 38.8 % EBITDA from Continuing Operations 449.2 42.8 % 591.9 39.3 % 31.8 % 697.9 37.4 % 953.8 35.6 % 36.7 % Net Income from Continuing Operations 399.1 38.0 % 479.4 31.8 % 20.1 % 647.1 34.7 % 787.1 29.4 % 21.6 % Net Income 396.4 37.7 % 470.6 31.2 % 18.7 % 634.6 34.0 % 775.7 29.0 % 22.2 % Cash Flow from Operations 352.0 33.5 % 407.1 27.0 % 15.7 % 522.7 28.0 % 558.2 20.8 % 6.8 % EARNINGS CONFERENCE CALL - PORTUGUESE : 7/26/2021 , 11am ( Brasília ) / 10am ( New York ) Webcast : click here / Phone : +55 11 3181-8565 ( code - Hypera ) Replay : +55 ( 11 ) 3193-1012 or +55 ( 11 ) 2820-4012 ( code - 5476238 # ) or website ir.hypera.com EARNINGS CONFERENCE CALL - ENGLISH : ( Simultaneous translation ) : 7/26/2021 , 11am ( Brasília ) / 10am ( New York ) Webcast : click here / Phone : US Toll Free +1 412 717-9627 | International +1 412 717-9627 ( code - Hypera ) Replay : +55 ( 11 ) 3193-1012 ( code - 8440138 # ) or website ir.hypera.com 1 Note : 1 Sell - out PPP 2Q21 ( Pharmacy Purchase Price ) , as informed by IQVIA , considers the average purchase price from pharmacies and chains . It does not consider the sell - out of the Buscopan family and the brands acquired from Takeda ; 2As informed by IQVIA , it excludes the infant formula segment IR contacts +55 ( 11 ) 3627-4206 +55 ( 11 ) 3627-4097 ri@hypera.com.br